ENG

Iskanje po repozitoriju

A- | A+ | Natisni

Iskalni niz:	išči po
	išči po
	išči po
	išči po
Vrsta gradiva:	* po starem in bolonjskem študiju
Jezik:
Išči po:
Opcije:	Prikaži samo zadetke s celotnim besedilom
	Ponastavi

1 - 2 / 2

High prevalence of probable sarcopenia and its associations with nutrition, cognitive, and physical function in hospitalized patients with Alzheimer’s clinical syndrome : a cross-sectional study
Vesna Simič, Nina Mohorko, Polona Rus Prelog, 2026, izvirni znanstveni članek

Opis: Background: Probable sarcopenia, indicated by low handgrip strength, is a prevalent condition among hospitalized older adults and may reflect broader functional and nutritional decline. Methods: We examined differences in nutritional, functional, and cognitive status between Alzheimer’s clinical syndrome (ACS) patients with probable sarcopenia and those without sarcopenia. A cross-sectional analysis was conducted on 194 hospitalized older adults with ACS. Probable sarcopenia was defined using European Working Group on Sarcopenia in Older People (EWGSOP2) handgrip strength thresholds. Results: Patients with probable sarcopenia (n = 137) had significantly lower Mini-Mental State Examination (MMSE) scores, Geriatric Nutritional Risk Index (GNRI), albumin, hemoglobin, and gait speed compared to those without. After age and sex adjustment, MMSE (p = 0.023), GNRI (p = 0.002), hemoglobin (p = 0.022), albumin (p = 0.003), and gait speed (p < 0.001) remained significantly different. In the sex- and age-adjusted multivariable model (adjusted R2 = 0.442), higher nutritional risk (β = 0.26, p = < 0.001), lower MMSE scores (β = 0.17, p = 0.029), polypharmacy (β = −4.20, p = 0.002), and slower gait speed (β = 4.12, p = 0.010) were associated with reduced handgrip strength. In the multivariable binary logistic regression model (adjusted for age and sex), moderate or high nutritional risk and slow gait speed emerged as independent predictors of probable sarcopenia, with OR 5.14 (95% CI 1.34–19.75; p = 0.017) and OR 3.13 (95% CI 1.30–7.52; p = 0.011), respectively. Conclusions: Probable sarcopenia in hospitalized older adults with ACS is highly prevalent and is associated with higher nutritional risk, poorer cognitive and physical function, and polypharmacy; its early recognition may help to guide more targeted nutritional and functional interventions.
Ključne besede: sarcopenia, muscle strength, Alzheimer’s disease, cognitive function, gait speed, nutrition risk
Objavljeno v RUP: 25.01.2026; Ogledov: 548; Prenosov: 4
Celotno besedilo (653,67 KB)
Gradivo ima več datotek! Več...

Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer’s disease
Alberto Benussi, Federica Agosta, Alba Rosa Alfano, Antonio Antico, Giuseppe Bellelli, Laura Bonanni, Gabriella Bottini, Marco Bozzali, Ovidio Brignoli, Giuseppe Bruno, Diego De Leo, 2025, pregledni znanstveni članek

Opis: This joint Position Paper, developed by the Italian Expert Panel on Alzheimer convened by the Italian Society of Neurology with participation from multiple scientific societies, outlines strategic guidelines for reorganizing the patient journey in the era of anti-amyloid monoclonal antibodies for Alzheimer’s disease. Emphasizing a multidisciplinary and integrated approach, the document recommends a patient journey that begins with early identification of cognitive impairment by General Practitioners, continues with specialized assessments at Memory and Dementia Centres, and leads, in carefully selected cases, to initiation of anti-amyloid monoclonal antibody therapy. It advocates the rational use of diagnostic tools, including plasma and cerebrospinal fluid biomarkers, advanced neuroimaging (MRI and PET), and genetic profiling (ApoE genotyping), not only to identify eligible patients but also to stratify those requiring alternative care strategies. The paper further defines minimum requirements for the accreditation of prescribing and infusion centres, highlighting the clinical competencies, structural resources, and inter-professional communication protocols necessary to ensure safety and appropriateness. Recognizing both the therapeutic potential and the organizational challenges associated with anti-amyloid monoclonal antibodies, the document aims to guide healthcare policymakers, institutions, and practitioners toward a coordinated reorganization of the diagnostic-therapeutic pathway, ensuring the safe and effective use of these treatments and ultimately improving outcomes and quality of care for individuals with Alzheimer’s disease.
Ključne besede: Alzheimer’s disease, disease-modifying therapies, anti-amyloid monoclonal antibodies, biomarkers, clinical implementation
Objavljeno v RUP: 22.12.2025; Ogledov: 460; Prenosov: 4
Celotno besedilo (1,22 MB)
Gradivo ima več datotek! Več...

Iskanje izvedeno v 0.01 sek.

Na vrh